Kopran Limited (KOPRAN.NS)
INR 221.0
(2.62%)
INR 221.0
(2.62%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 675.44 Million INR | 35.87% |
| 2022 | 452.83 Million INR | -41.13% |
| 2021 | 769.16 Million INR | 6.23% |
| 2020 | 724.08 Million INR | 90.34% |
| 2019 | 380.41 Million INR | -5.49% |
| 2018 | 402.51 Million INR | 69.08% |
| 2017 | 238.06 Million INR | -4.92% |
| 2016 | 250.38 Million INR | 133.6% |
| 2015 | 107.18 Million INR | 127.4% |
| 2014 | -391.24 Million INR | -327.76% |
| 2013 | 171.78 Million INR | 54.5% |
| 2012 | 111.18 Million INR | -25.9% |
| 2011 | 150.04 Million INR | 27.69% |
| 2010 | 117.5 Million INR | 69.09% |
| 2009 | 69.49 Million INR | 232.29% |
| 2008 | -52.52 Million INR | 0.0% |
| 2007 | - INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 142.89 Million INR | 122.05% |
| 2023 FY | 615.26 Million INR | 35.87% |
| 2023 Q4 | 180.98 Million INR | -20.42% |
| 2023 Q3 | 227.43 Million INR | 12.65% |
| 2023 Q2 | 201.89 Million INR | 561.46% |
| 2023 Q1 | 30.52 Million INR | -75.96% |
| 2022 Q1 | 140.23 Million INR | -42.23% |
| 2022 FY | 452.83 Million INR | -41.13% |
| 2022 Q4 | 126.98 Million INR | 11.63% |
| 2022 Q3 | 113.76 Million INR | 55.28% |
| 2022 Q2 | 73.26 Million INR | -47.76% |
| 2021 Q1 | 65.78 Million INR | -64.47% |
| 2021 FY | 769.16 Million INR | 6.23% |
| 2021 Q2 | 211.92 Million INR | 222.12% |
| 2021 Q4 | 242.75 Million INR | 0.12% |
| 2021 Q3 | 242.46 Million INR | 14.41% |
| 2020 Q4 | 185.17 Million INR | -0.61% |
| 2020 FY | 724.08 Million INR | 90.34% |
| 2020 Q1 | 175.77 Million INR | 13.13% |
| 2020 Q2 | 185.87 Million INR | 5.75% |
| 2020 Q3 | 186.31 Million INR | 0.24% |
| 2019 Q3 | 97.58 Million INR | 19.32% |
| 2019 Q1 | 52.62 Million INR | -56.93% |
| 2019 Q4 | 155.37 Million INR | 59.21% |
| 2019 FY | 380.41 Million INR | -5.49% |
| 2019 Q2 | 81.78 Million INR | 55.4% |
| 2018 Q2 | 106.05 Million INR | 184.54% |
| 2018 FY | 402.51 Million INR | 69.08% |
| 2018 Q4 | 122.19 Million INR | -10.8% |
| 2018 Q1 | 37.27 Million INR | -56.58% |
| 2018 Q3 | 136.99 Million INR | 29.17% |
| 2017 Q1 | 10.4 Million INR | -91.58% |
| 2017 Q2 | 45.2 Million INR | 334.62% |
| 2017 FY | 238.06 Million INR | -4.92% |
| 2017 Q4 | 85.84 Million INR | -12.41% |
| 2017 Q3 | 98 Million INR | 116.81% |
| 2016 FY | 250.38 Million INR | 133.6% |
| 2016 Q2 | 36.4 Million INR | 73.33% |
| 2016 Q4 | 123.52 Million INR | 39.73% |
| 2016 Q3 | 88.4 Million INR | 142.86% |
| 2016 Q1 | 21 Million INR | -59.05% |
| 2015 Q1 | 6.1 Million INR | 0.0% |
| 2015 FY | 107.18 Million INR | 127.4% |
| 2015 Q3 | 21.5 Million INR | -24.03% |
| 2015 Q4 | 51.28 Million INR | 138.54% |
| 2015 Q2 | 28.3 Million INR | 363.93% |
| 2014 Q1 | 30.3 Million INR | -58.43% |
| 2014 FY | -391.24 Million INR | -327.76% |
| 2013 Q1 | 27.9 Million INR | -45.86% |
| 2013 Q3 | 30.7 Million INR | 0.0% |
| 2013 FY | 171.78 Million INR | 54.5% |
| 2013 Q4 | 72.88 Million INR | 137.4% |
| 2012 Q4 | 51.53 Million INR | 1.05% |
| 2012 Q2 | 60.4 Million INR | 15.49% |
| 2012 Q1 | 52.3 Million INR | 0.0% |
| 2012 FY | 111.18 Million INR | -25.9% |
| 2012 Q3 | 51 Million INR | -15.56% |
| 2011 FY | 150.04 Million INR | 27.69% |
| 2010 FY | 117.5 Million INR | 69.09% |
| 2009 FY | 69.49 Million INR | 232.29% |
| 2008 FY | -52.52 Million INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott India Limited | 13.79 Billion INR | 95.103% |
| Cipla Limited | 105.7 Billion INR | 99.361% |
| Gland Pharma Limited | 16.45 Billion INR | 95.894% |
| GlaxoSmithKline Pharmaceuticals Limited | 13.6 Billion INR | 95.034% |
| Marksans Pharma Limited | 7.79 Billion INR | 91.331% |
| NGL Fine-Chem Limited | 416.27 Million INR | -62.261% |
| Pfizer Limited | 9.61 Billion INR | 92.973% |
| Sanofi India Limited | 12.19 Billion INR | 94.46% |
| SMS Pharmaceuticals Limited | 1.34 Billion INR | 49.599% |
| TTK Healthcare Limited | 249.89 Million INR | -170.298% |